SEATTLE and COPENHAGEN, Denmark, Sept. 22, 2011 /PRNewswire/ -- CMC Biologics officially marked the opening of its state-of-the-art biopharmaceutical manufacturing facility, known as PF2, with a ribbon cutting ceremony on Wednesday, September 21, at its Bothell, Washington campus. The expansion of PF2 duplicates capacity and supports commercial manufacturing. Local political and business leaders attended the event.
Director of Commerce of Washington State, Rogers Weed, who presided over the dedication of the facility said, "I'm delighted to see Washington State's life sciences sector grow and expand. This region benefits in many ways from companies like CMC Biologics, which manufactures clinical and commercial materials for companies throughout the world. This is an industry that will provide the people of Washington State with jobs and prosperity into the next century."
According to David Kauffmann, Chairman of the Board of CMC Biologics and Managing Director of European Equity Partners, "Our vision has always been to be a global market leader in contract biopharmaceutical process development and manufacturing services. This facility expansion represents one more step toward making that vision a reality."
"We are proud of the positive impact of this project on the local economy. CMC Biologics used mainly local contractors for the expansion and once the facility is operating at full capacity, we anticipate adding about 35 new employees to staff it," noted Gustavo F. Mahler, Ph.D., Global Chief Operations Officer of CMC Biologics. "I'd like to thank our contractors as well as all of the employees at CMC Biologics who were instrumental in bringing this project in on time and on budget."
The expansion project was led by Yonkers Industries, with support from Sellen, BMWC Constructors, Holaday-Parks, and Precision Electric Group, as well as other subcontractors.
About CMC Biologics
CMC Biologics (www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and in-market production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes.
|SOURCE CMC Biologics|
Copyright©2010 PR Newswire.
All rights reserved